The aim of this investigation is preparation of Mitomycin-C encapsulated with chitosan nanoparticles synthesis using ionic gelation technique for intraves ical controlled drug delivery systems. This study was conducted in vitro . Cumulative amount of drug released from the nanoparticles was calculated. Mitomycin-C release studies were examined for different pH values. During the drug loading and release studies, initial amount of drug was changed ( i.e. , 0.5, 1.25 and 2.5 mg) to get different release profiles and the release studies were repeated ( n = 6). The loading efficiencies of Mitomycin-C with three different initial concentrations 0.5mg/ml, 1.25 mg/ml and 2.5 mg/ml into chitosan nanoparticles were 54.5%, 47.1% and 36.4%, respectively. For different pH values, the cumulative releases of Mitomycin-C from chitosan nanoparticles were 47% and 53% for pH 6.0 and 7.4, respectively ( p < 0.01). For different drug doses, the cumulative releases of Mitomycin-C (MMC) from Chitosan nanoparticles were 44%, 53% and 65% for 0.5 mg/mL, 1.25 mg/mL and 2.5 mg/mL respectively ( p < 0.01). The anticancer activity of Mitomycin-C loaded chito san nanoparticles was measured in T24 bladder cancer cell line in vitro , and the results revealed that the 2.5 MMC coated Chitosan nanoparticles had better tumor cells decline activity. From this investigation, we conclude that the drug encapsulated synthesized chitosan nanoparticles possess a high ability to be used as pH and dose responsive drug delivery system. This systematic investigation demonstrates a promising future for the intravesical installation in treatment of the superficial bladder cancer.
KeywordsChitosan NanoparticlesMitomycin-CLow Releasing Drug KineticsIntravesical TherapyBladder Tumor
Cui, J., Wang, W., Chen, S., Chen, P., Yang, Y., Guo, Y., Zhu, Y., Chen, F. and Shi, B. (2016) Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis. Medicine, 95, Article No: e2572. https://doi.org/10.1097/MD.0000000000002572
Zargar, H., Aning, J., Ischia, J., So, A. and Black, P. (2014) Optimizing Intravesical Mitomycin C Therapy in Non-Muscle-Invasive Bladder Cancer. Nature Reviews Urology, 11, 220-320. https://doi.org/10.1038/nrurol.2014.52
Lightfoot, A.J., Breyer, B.N., Rosevear, H.M., Erickson, B.A., Konety, B.R. and O’Donnell, M.A. (2014) Multi-Institutional Analysis of Sequential Intravesical Gemcitabine and Mitomycin C Chemotherapy for Non-Muscle Invasive Bladder Cancer. Urologic Oncology, 32, 35.e.15-35.e.9.
Porten, S.P., Leapman, M.S. and Greene, K.L. (2015) Intravesical Chemotherapy in Non-Muscle-Invasive Bladder Cancer. Indian Journal of Urology, 31, 297-303. https://doi.org/10.4103/0970-1591.166446
Sylvester, R.J., Oosterlinck, W. and Van der Meijden, A. (2004) A Single Immediate Postoperative Instillation of Chemotherapy Decreases the Risk of Recurrence in Patients with Stage Ta T1 Bladder Cancer: A Meta-Analysis of Published Results of Randomized Clinical Trials. The Journal of Urology, 171, 2186-2190. https://doi.org/10.1097/01.ju.0000125486.92260.b2
Abern, M.R., Owusu, R.A. and Anderson, M.R. (2013) Perioperative Intravesical Chemotherapy in Non–Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Journal of the National Comprehensive Cancer Network, 11, 477-484. https://doi.org/10.6004/jnccn.2013.0060
Sylvester, R.J., Oosterlinck, W. and Witjes, J.A. (2008) The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials. European Urology, 53, 709-719. https://doi.org/10.1016/j.eururo.2008.01.015
Lammers, R.J., Witjes, J.A., Inman, B.A., Leibovitch, I., Laufer, M., Nativ, O. and Colombo, R. (2011) The Role of a Combined Regimen with Intravesical Chemotherapy and Hyperthermia in the Management of Non-Muscle-Invasive Bladder Cancer: A Systematic Review. European Urology, 60, 81-93. https://doi.org/10.1016/j.eururo.2011.04.023
Di Stasi, S.M., Giannantoni, A., Giurioli, A., Valenti, M., Zampa, G., Storti, L., Attisani, F., De Carolis, A., Capelli, G. and Vespasiani, G. (2006) Sequential BCG and Electromotive Mitomycin versus BCG Alone for High-Risk Superficial Bladder Cancer: A Randomized Controlled Trial. The Lancet Oncology, 7, 43-51. https://doi.org/10.1016/S1470-2045(05)70472-1
Duncan, R. (2003) The Dawning Era of Polymer Therapeutics. Nature Reviews Drug Discovery, 2, 347-360. https://doi.org/10.1038/nrd1088
Ferrari, M. (2005) Cancer Nanotechnology: Opportunities and Challenges. Nature Reviews Cancer, 5, 161-171. https://doi.org/10.1038/nrc1566
Pieter, V. and Raymond, M.S. (2016) Biologically-Inspired Drug Delivery Systems. Advanced Drug Delivery Reviews A, 106, 1-2.
Vaseashta, A. (2008) Functionalized Nanoscale Materials, Devices and Systems, NATO Science for Peace and Security Series B: Physics and Biophysics. Springer, New York.
Akbal, O., Erdal, E., Vural, T., Kavaz, D. and Denkbas, E.B. (2017) Comparison of Protein- and Polysaccharide-Based Nanoparticles for Cancer Therapy: Synthesis, Characterization, Drug Release, and Interaction with a Breast Cancer Cell Line, Artificial Cells. Nanomedicine, and Biotechnology, 45, 193-203. https://doi.org/10.3109/21691401.2016.1170694
Kavaz, D., Odabas, S., Denkbas, E.B. and Vaseashta, A. (2012) A Practical Methodology of IgG Purification via Chitosan Based Magnetic Nanoparticles. Digest Journal of Nanomaterials and Biostructures, 7, 1165-1177.
Rampino, A., Borgogna, M., Blasi, P., Bellich, B. and Cesaro, A. (2013) Chitosan Nanoparticles: Preparation, Size Evolution and Stability. International Journal of Pharmaceutics, 455, 219-228.
Dyer, M., Hinchcliffe, M., Watts, P., Castile, J., Jabbal-Gill, I., Nankervis, R., Smith, A. and Illum, L. (2002) Nasal Delivery of Insulin Using Novel Chitosan Based Formulations: A Comparative Study in Two Animal Models between Simple Chitosan Formulations and Chitosan Nanoparticles. Pharmaceutical Research, 19, 998-1008. https://doi.org/10.1023/A:1016418523014
Kavaz, D., Odabas, S., Guven, E., eMobile, M. and Denkbas, E.B. (2010) Bleomycin Loaded Magnetic Nanoparticles as Multifunctional Nanocarriers. Journal of Bioactive and Compatible Polymers, 25, 305-318. https://doi.org/10.1177/0883911509360735
Rafiee, E. and Eavani, S. (2014) PH-Responsive Controlled Release of Epirubicin from Fe@Si-Pw Hybrid Nanoparticles. Materials Science and Engineering C: Materials for Biological Applications, 39, 340-343.
Yu, Y., Chen, C.K., Law, W.C., Weinheimer, E., Sengupta, S. and Prasad, P.N. (2014) Polylactide-Graft-Doxorubicin Nanoparticles with Precisely Controlled Drug Loading for pH-Triggered Drug Delivery, S. Biomacromolecules, 15, 524-532. https://doi.org/10.1021/bm401471p
Zhang, Y., Li, J., Lang, M., Tang, X., Li, L. and Shen, X. (2011) Folate-Functionalized Nanoparticles for Controlled 5-Fluorouracil Delivery. Journal of Colloid and Interface Science, 354, 202-209.
Vivek, R., NipunBabu, V., Thangam, R., Subramanian, K.S. and Kannan, S. (2013) PH-Responsive Drug Delivery of Chitosan Nanoparticles as Tamoxifen Carriers for Effective Anti-Tumor Activity in Breast Cancer Cells. Colloids and Surfaces B: Biointerfaces, 111, 117-123.
Vishvajit, A.K., Deepali, M.J. and Vilasrao, J.K. (2010) Nanosuspension a Novel Drug Delivery System. International Journal of Pharma and Bio Sciences, 1, 352-360.
Panyam, J., Zhou, W.Z., Prabha, S.K. and Labhasetwar, V. (2002) Rapid Endo-Lysosomal Escape of Poly(DL-lactide-co-glycolide) Nanoparticles: Implications for Drug and Gene Delivery. The FASEB Journal, 16, 1217-1226. https://doi.org/10.1096/fj.02-0088com
Raman, S., Kandula, M.P., Jacob, J.A., Soundararajan, K., Ramar, T., Palani, G., Muthukalingan, K. and Shanmugam, A. (2012) Cytotoxic Effect of Green Synthesized Silver Nanoparticles Using Melia Azedarach against in Vitro HeLa Cell Lines and Lymphoma Mice Model. Process Biochemistry, 47, 273-279.
Dongwei, W. and Weiping, Q. (2008) Facile Synthesis of Ag and Au Nanoparticles Utilizing Chitosan as a Mediator Agent. Colloids and Surfaces, 62, 136-142.
McEvoy, G.K. (2007) AHFS 2007 Drug Information Essentials. American Society of Health-System Pharmacists, Inc., Bethesda, 1139-1141.
Shi, Y., Wan, A., Shi, Y., Zhang, Y. and Chen, Y. (2014) Experimental and Mathematical Studies on the Drug Release Properties of Aspirin Loaded Chitosan Nanoparticles. BioMed Research, 2014, Article ID: 613619.
Liu, Y., Li, K., Liu, B. and Feng, S.S. (2010) A Strategy for Precision Engineering of Nanoparticles of Biodegradable Copolymers for Quantitative Control of Targeted Drug Delivery. Biomaterials, 31, 9145-9155.
Beijnen, J.H., Wiese, G. and Underberg, W.J. (1985) Aspects of the Chemical Stability of Doxorubicin and Seven Other Anthracyclines in Acidic Solution. Pharmaceutisch Weekblad, Scientific Edition, 21, 109-116. https://doi.org/10.1007/BF01968712
Au, J.L., Badalament, R.A., Wientjes, M.G., Young, D.C., Warner, J.A., Venema, P.L., Pollifrone, D.L., Harbrecht, J.D., Chin, J.L. and Lerner, S.P. (2001) Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial. Journal of the National Cancer Institute, 93, 597-604. https://doi.org/10.1093/jnci/93.8.597
Zhang, H., Wang, C., Chen, B. and Wang, X. (2012) Daunorubicin-TiO2 Nanocomposites as a “Smart” pH-Responsive Drug Delivery System. International Journal of Nanomedicine, 7, 235-242.
Gan, Q. and Wang, T. (2007) Chitosan Nanoparticle as Protein Delivery Carrier— Systematic Examination of Fabrication Conditions for Efficient Loading and Release. Colloids and Surfaces B Biointerfaces, 59, 24-34.
Nishiyama, M., Suzuki, K. and Kumazaki, T. (1997) Molecular Targeting of Mitomycin C Chemotherapy. International Journal of Cancer, 72, 649-665. https://doi.org/10.1002/(SICI)1097-0215(19970807)72:4 3.0.CO;2-6
Crooke, S.T. and Bradner, W.T. (1976) Mitomycin C: A Review. Cancer Treatment Reviews, 3, 121-139.
Ko, J.C., Chen, J.C., Wang, T.J., Zheng, H.Y., Chen, W.C, Chang, P.Y. and Lin, Y.W. (2016) Astaxanthin Down-Regulates Rad51 Expression via Inactivation of AKT Kinase to Enhance Mitomycin C-Induced Cytotoxicity in Human Non-Small Cell Lung Cancer Cells. Biochemical Pharmacology, 105, 91-100.
Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y. and Zeng, Y. (2014) Hyaluronic Acid Chitosan Nanoparticles for Co-Delivery of MiR-34a and Doxorubicin in Therapy against Triple Negative Breast Cancer. Biomaterials, 35, 4333-4344.
Kini, D.B. and Panda, D. (2015) Mechanism of Anti-Cancer Activity of Benomyl Loaded Nanoparticles in Multidrug Resistant Cancer Cells. Journal of Biomedical Nanotechnology, 11, 877-889. https://doi.org/10.1166/jbn.2015.1998